Eytan M. Stein, MD
Results from a phase I/II study demonstrated that enasidenib (AG-221) is well-tolerated and associated with a median overall survival (OS) of more than 9 months in patients with IDH2-mutated relapsed/refractory acute myeloid leukemia (AML).
An ongoing phase II study, which has now been completely accrued, is examining enasidenib at 100 mg daily in patients with relapsed/refractory AML.
Steyn EM, Dinardo DC, Pollyea DA, et al. Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study. J Clin Oncol 35, 2017 (suppl; abstr 7004).
... to read the full story